Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

MET inhibitors for non-small cell lung cancer

Treatment of ALK+ lung cancer with crizotinib, Profile 1007

Phase I study examining PI 3 kinase inhibitor for various tumours

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial

Tobacco control and prevention through social media

Cancer prevention and epidemiology in Russia

Importance of cancer prevention

Epigenetics of cancer and changes in DNA modification in tumours

Drug development in small cell and non-small cell lung cancer